2025 Study: Caftrio (Tricafta) Helps Cystic Fibrosis Patients Do More Intense Exercise

A German study found that the drug Caftrio (a combination of elexacaftor, tezacaftor, and ivacaftor, sold as Tricafta in the U.S.) may help adults with cystic fibrosis engage in more high-intensity exercise, although regular exercise remains key for all patients.

The study involved 56 adults with cystic fibrosis who completed a 3.5-week exercise program. Of these, 39 took Caftrio (Tricafta) and 17 did not. All participants were in stable health and continued to take their medications throughout the study.

The program included five 45-minute training sessions per week: three cardio sessions on an exercise bike, one strength training session to develop strength endurance, and another one of various sports activities under the supervision of physiotherapists.

Two key indicators were measured: VO2peak (the maximum amount of oxygen a person can use during exercise) and Wpeak (the maximum power achieved during exercise) to assess improvements in physical fitness.

Exercise resulted in significant increases in both VO2peak and Wpeak for all patients, regardless of whether they took Caftrio (Tricafta). Both groups showed similar improvements in fitness. However, patients with lower fitness levels at the start of the program (defined as VO2peak 81% or less of predicted value) showed greater improvements than those who were already in better shape. There were no statistically significant changes in body mass index, fat mass index, or weight. Lung function remained unchanged (as measured by percent predicted forced expiratory volume in 1 second).

A particular benefit: Patients on Caftrio (Tricafta) spent more time in the high-intensity exercise zone compared with the control group. There was also a positive association between very high-intensity exercise and both VO2peak and Wpeak in patients taking the targeted drug.

Conclusions:
Both groups showed improvements in physical performance after the program, regardless of treatment. However, Caftrio (Tricafta) seemed to help people engage in more intense physical activity.

It is worth noting that the short duration of the study does not allow conclusions to be drawn about long-term benefits. “Despite the effectiveness of CFTR modulators, regular physical activity remains necessary to maintain and improve physical performance in people with cystic fibrosis,” the researchers note.

The results, published in the journal Pediatric Pulmonology, highlight the importance of combining medication with an active lifestyle for patients with cystic fibrosis, as well as the need for studies of varying lengths in real-world settings to be able to translate the results into practical guidelines and advice for people with cystic fibrosis.